Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00471536 · OUTCOME

Adverse Events Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0

Pazopanib in Treating Patients With Metastatic Urothelial Cancer · Source last updated 2014-05-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Every 4 weeks during treatment (maximum duration was 44 weeks)

What was measured

The maximum grade for each adverse event considered to be at least possibly related to treatment will be recorded. Frequency tables will be constructed.

Analysis population: Eighteen of the 19 participants accrued to the study were evaluable for adverse events.

Groups in this outcome

Treatment (Enzyme Inhibitor Therapy)

Patients receive oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Enzyme Inhibitor Therapy)18

Reported measurements

Grade 3 Adverse Events
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Enzyme Inhibitor Therapy)7Not reportedNot reportedNot reportedNot reported
Grade 4 or Higher Adverse Events
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Enzyme Inhibitor Therapy)0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        7
    title
    Grade 3 Adverse Events
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Grade 4 or Higher Adverse Events
denoms
  1. counts
    1. group Id
      OG000
      value
      18
    units
    Participants
description
The maximum grade for each adverse event considered to be at least possibly related to treatment will be recorded. Frequency tables will be constructed.
groups
  1. description
    Patients receive oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Treatment (Enzyme Inhibitor Therapy)
param Type
NUMBER
population Description
Eighteen of the 19 participants accrued to the study were evaluable for adverse events.
reporting Status
POSTED
time Frame
Every 4 weeks during treatment (maximum duration was 44 weeks)
title
Adverse Events Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice